FDA Warning Letters to ZIIP and Nihon Kohden Cite Device Marketing and Software Compliance Issues
In two separate warning letters, the FDA cited ZIIP for alleged marketing authorization, promotional claims, and quality system controls violations related to its facial devices, and Nihon Kohden Digital Health Solutions for modifications to its patient monitoring software.
Medtech Insight - July 15, 2026

Stada Report: Half Of European Consumers Using AI But ‘Trust Still Has A Human Face’
Stada's 2026 Health Report finds 55% of Europeans using AI for health. But trust is lagging behind adoption, with CEO Peter Goldschmidt positioning pharmacists as the human anchor in a hybrid model of care.
HBW Insight - July 15, 2026

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success
£28m investment in AI diagnostics for the UK health service is welcome, but only one piece of the puzzle in reducing wait times.
Medtech Insight - July 15, 2026

Warburg Pincus Kicks Off Therapy-Focused India Platform Push With Integrace Buyout
Warburg Pincus rolls out therapy-focused, brand-led platform push in India with Integrace as the cornerstone asset and ex-MSD and Abbott India chief Rehan Khan at the helm.
Scrip - July 15, 2026

SpotitEarly Bets On Dogs, Breath And AI For Early Cancer Detection
SpotitEarly CEO Shlomi Madar makes the case for breath-based cancer screening — trained beagles, sensors and AI reading VOCs — as GRAIL's NHS-Galleri miss reopens how MCED tests should be judged. He touts early-stage sensitivity, a de novo path and near-term PINK data.
Medtech Insight - July 15, 2026

Philips Targets Rural Hospitals And Surgery Centers With Modular PM 6000
Philips has launched the IntelliVue PM 6000 Series with a clear target: rural hospitals and ambulatory surgery centers handling more complex patients with fewer staff and shrinking budgets — facilities being asked to match large-system standards with a fraction of the resources.
Medtech Insight - July 15, 2026

HUYABIO’s HBI-8000 Combo Meets Phase III Primary Endpoint in Advanced Melanoma
HUYABIO's Phase III win adds a new late-stage contender to the advanced melanoma pipeline, with attention now shifting to detailed clinical data and the company's regulatory roadmap.
Scrip - July 15, 2026

Formycon Partners With OneSource For Biosimilar Manufacturing
Formycon has signed a manufacturing partnership with India-based CDMO OneSource, gaining integrated drug substance and drug product capabilities as it executes its FYB4Growth strategy.
Generics Bulletin - July 15, 2026

Actavis Fails To Escape Key Generics Collusion Claims
A federal judge has preserved most product-specific claims against Actavis, finding enough evidence of alleged coordination over pricing, customers and market share for a jury to consider.
Generics Bulletin - July 15, 2026

Bisoprolol And Ezetimibe Surge In A Busy June For UK Rises
Two presentations of bisoprolol topped our Biggest Risers table for June – but the anticoagulant was far from the only generic experiencing steep UK price rises last month, with recently-launched ezetimibe increasing its average price by more than ten times.
Generics Bulletin - July 15, 2026

Taiho VC Arm Bolsters Early R&D Support For Japan Ventures
Taiho's domestic venture capital arm adds capabilities and restructures in bid to better support Japanese academic spinoffs and other startups in the country.
Scrip - July 15, 2026

ZS’s Roffman: China Leads The Way On Patient Trust In AI
A three-country survey of healthcare stakeholders in the US, Germany and China indicates that patients’ confidence in healthcare AI tools now almost matches the trust they have in healthcare professionals. Jon Roffman, ZS global head of biopharma, says attitudes to AI are changing fast.
In Vivo - July 15, 2026

Celcuity Wins FDA Approval For PAM Inhibitor Revtorpyk In Breast Cancer
Celcuity's Revtorpyk wins FDA approval as the first drug to block every major node of the PI3K/mTOR pathway.
Scrip - July 15, 2026

World-First Phase III Win For Kelun’s Chemo-Free Combo In NSCLC
With progression-free survival as the only primary endpoint, the China Phase III OptiTROP-Lung06 trial showed sac-TMT plus Keytruda bested Keytruda plus chemotherapy in the first-line treatment of PD-L1-negative non-squamous NSCLC.
Scrip - July 15, 2026

AAIC Data Raises Promise Of Alzheimer’s Prognoses From Blood
Harvard Medical School study finds that p-tau217 blood tests were able to predict risk of developing cognitive impairment over 10 years.
Medtech Insight - July 15, 2026

Why Opella Is Betting On The Liver
Exclusive Interview: HBW Insight speaks to Opella’s global brand general manager for Essentiale, Nikunj Thakker, about how the firm is using this brand to build a liver wellness category in Western markets, targeting early-stage fatty liver disease.
HBW Insight - July 15, 2026

Galux Positions AI Antibody Platform For Global Stage
Korean biotech Galux tells Scrip how it is gaining international credibility through global research partnerships, underpinned by its proprietary AI-powered antibody design platform.
Scrip - July 15, 2026